Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib (OPTIMIS)
OPTIMIS - Outcomes of HCC Patients Treated With TACE Followed or Not Followed by Sorafenib and the Influence of Timing to Initiate Sorafenib
Sponsor: Bayer
A observational or N/A phase clinical study on Carcinoma, Hepatocellular, this trial is completed. The trial is conducted by Bayer and has accumulated 11 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Dec 2018 — Jan 2021 [monthly]
Completed
▶ Show 6 earlier versions
-
Jun 2018 — Dec 2018 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Dec 2017 — Apr 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Sep 2017 — Dec 2017 [monthly]
Active Not Recruiting NA
-
Jun 2017 — Sep 2017 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Jun 2017 [monthly]
Active Not Recruiting NA
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Multiple Locations, Austria , Multiple Locations, Brazil , Multiple Locations, Canada , Multiple Locations, China , Multiple Locations, Czechia , Multiple Locations, Denmark , Multiple Locations, Egypt , Multiple Locations, France , Multiple Locations, Greece , Multiple Locations, Hong Kong and 21 more locations